大和发表研究报告指出，药明生物发盈喜，预计上半年收入按年升16%，高于市场预期的9%，占公司全年指引的12%至15%；毛利率改善3.6个百分点，股东应占利润按年增长约56%，高于市场预期的30%。公司认为增长是由于成功执行Follow and Win the Molecule策略、ADC及双特异性抗体等技术平台快速成长、研究服务收入增长及欧洲生产基地产能提升等。该行维持对其“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.